Table 1.

GBM Cell Line Information

GBM Cell Line	Primary/Recurrent	Patient Sex	IDH Status	PDGFRA Amplification	NF1 Mutation	PTEN Mutation	TP53 Mutation	EGFR Mutation/CNA	MGMT Methylation (%)
G-13063	Primary	Female	wt	✓	✓				52.4
G-12746	Primary	Male	wt				✓	✓	92.2
G-13181	Primary	Female	wt		✓				39.6
G-16302	Recurrent	Female	wt		✓				37.1
G-13514	Primary	Female	wt					✓	96.2
G-17969	Recurrent	Female	wt					✓	93
G-11849	Primary	Female	wt	✓		✓			58.2
G-11849R	Recurrent	Female	wt	✓		✓			86.6
U87	Established	Male	wt			✓

Provided is information on experimental cells used—8 patient-derived lines at low passage (<30) (G-13063, G-12746, G-13181, G-16302, G-13514, G-17969, G-11849, G-11849R) and U87 GBM cell line, patient sex, primary/recurrent status, main genomic alterations of original tumor; and patient-derived cell line MGMT DNA methylation levels. All 8 patient-derived lines were used for functional in vitro experiments; G-13063 and G-16302 lines were used for in vivo experiments; G-13063, G-16302, and U87 cells were used for RNA-seq experiments. Abbreviation: CNA, copy number alteration.